HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the... HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Disclosures of HUTCHMED (China)
Explore HUTCHMED (China)'s complete collection of publicly available corporate disclosures, including annual reports, sustainability reports, financial statements, ESG data spreadsheets, and related web publications. Each document is sourced directly from HUTCHMED (China)'s official channels and fully traceable to its official company sources.
The table below lists all of HUTCHMED (China)'s' corporate disclosure by name and reporting period, ensuring full transparency and easy access.
Fiscal Year / Type
Languages
20251 disclosure
Sustainability Report
en
20242 disclosures
Sustainability Report
en
Annual Report
en
20233 disclosures
ESG Data Spreadsheet
en
Sustainability Report
en
Annual Report
en
20222 disclosures
Sustainability Report
en
20-F
20212 disclosures
20-F
Sustainability Report
en
20202 disclosures
20-F
Sustainability Report
en
Real-Time Disclosures Datafeed
Get Notified Within Seconds of New Corporate Disclosures
Tracenable is building a high-speed disclosure monitoring system that delivers instant alerts when companies publish new reports or data. Could a real-time datafeed (via SFTP, RSS or API) enhance your investment or analytical workflows?
Account Restricted
Your account has been restricted and you no longer have access to paid features.
Contact our support team orupgrade your planto unblock your account.